Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Immune reconstitution after venetoclax-based treatments in CLL

View Full Paper
Ask AI
Bookmark
Share

Authors

BHBenjamin Heyman

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows humoral immune recovery post-venetoclax in CLL, suggesting treatment effectiveness.

Key Points

  • This research aims to evaluate the reconstitution of immunoglobulin levels after venetoclax-based treatments in CLL patients.
  • Retrospective chart review of patients treated with venetoclax from 2012-2024.
  • Evaluation of immunoglobulin levels before and after venetoclax treatment.
  • Analysis included various treatment regimens: monotherapy, combinations with rituximab or obinutuzumab, and with ibrutinib.
  • 74% of patients achieved undetectable minimal residual disease (uMRD) after treatment.
  • IgA levels decreased during treatment but began to improve significantly 12 months post-treatment.
  • Treatment with venetoclax plus CD20 monoclonal antibody resulted in reduced IgA levels initially, with a recovery noted afterwards.

Cite This Study

Benjamin Heyman (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfddhttps://doi.org/10.1182/blood-2025-7403
View Full Paper
Ask AI
Bookmark
Share